**PATENT** 

Attorney Docket No.: 06478.1442

IN THE UNITED STATES PATEN	NT AND TRADEMARK OFFICE 2	
In re Application of:	) 1 2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
Claude NÉGRIER et al.	) jc586	\
Serial No.: Not Yet Assigned	) Group Art Unit: Not Yet Assign	ed
Filed: Concurrently Herewith	) Examiner: Not Yet Assigned	
For: DNA CONSTRUCT FOR THE TISSUE EXPRESSION OF A BLOOD COAGULATION FACTOR	) ) )	
Assistant Commissioner for Patents Washington, D.C. 20231		
Sir		

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Copies of the listed documents are attached and the United States counterpart, U.S. Patent No. 5,656,358 of the non-English document, WO 93/00438 is enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

LAW OFFICES
(NEGAN, HENDERSON, ARABOW, GARRETT, & DUNNER, L. L. P. 300 I STREET, N. W. 3HINGTON, D. C. 20005 202-408-4000

BEST AVAILABLE COPY

astitute "prior art." If the Examiner applies any of the documents as prior art against any claim

in the application and applicants determine that the cited documents do not constitute "prior art"

under United States law, applicants reserve the right to present to the office the relevant facts and

law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability

of the disclosed invention over the listed documents, should one or more of the documents be

applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the

fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Reg. Not. 32,220

Date: April 27, 2000

INNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P. 1300 I STREET, N. W.

202-408-4000

LAW OFFICES

ASHINGTON, D. C. 20005

- 2 -

BEST AVAILABLE COPY

## INFORMATION DISCLOSURE CITATION (Use several she ts if necessary)

•			(Use several:	she ts if necessary)			4
	-64°	78.1442		Serial No.: Not Yet Assigned			<del>- 268</del>
	Clau	ude NÉGRIER et al.					
-	Con	currently Herwith		Group	Not Yet	Assigned	, jo
			U.S. PATE	ENT DOCUMENTS			
		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriat
21111101 1111001	++	5,565,358	10/15/96	Marguerie de Rotrou et al.	435	320.1	9/30/94
			FOREIGN PA	ATENT DOCUMENTS			
	$\prod$	Document Number	Date	Country	Class	Sub Class	Translati n Yes or No
	++	WO 93/00438	01/07/93			<u> </u>	YES
		OTHER DOCUMEN	TS (Including	Author, Title, Date, Pertinent	Pages, Etc	c.)	
		Thrombosis and Haem	iostasis, voi. 7	Gene Transcription During the 4, pp. 210-212 (1995 ).			
		KURACHI, Kotoku et a	ıl., "Regulatory 1995).	Mechanism of the Faxtor IX Ge			
				onal Characterization of the 5'-F emistry, Vol. 265, No. 12, pp. 70	Regulatory 62-7068 (A	Region of April 25, 19	Human Factor IX 990).
		CAMERINO, G. et al., Coagulation Factor IX	"Regional Loc Gene (Hemop	alization on the Human X Chron hilia B Locus)", Proc. Natl. Acad	nosome ar I. Sci., Vol	nd Polymo . 81, pp. 4	rphism of the 98-502 (Jan. 1984)
		Factor B)", Biochemis	try, Vol. 24, pp	le Sequence of the Gene for Hu . 3736-3750 (1985).			
		Chromosome", Ann. I	łum. Genet., v	Haemophilia B (Factor IX) Locu ol. 48, pp. 145-152 (1984).			
		ROBERTS, Harold R., "Molecular Biology of Hemophila B", Thrombosis and Haemostasis, Vol. 70, pp. 1-9 (1993).					
		Factor IX Into Mouse	Liver", Blood,	ociated Viral Vector-Mediated Ge Vol. 91, No. 12, pp. 4600-4607 (	04110 101		
		WHITE, Steve J. et a	I., "Long-Term tinocytes In Viv	Expression of Human Clotting F vo", Human Gene Therapy, Vol.	actor IX F 9, pp. 118	rom Retro 7-1195 (N	
		BARU, Moshe et al., Factor IX in Mice", In	"Retroviral-Me tervirology, Vo	diated In Vivo Gene Transfer int I. 38, pp. 356-360 (1995).	o Muscle	Cells and	Synthesis of Huma
	K 9	Mediated Gene Tran	sfer: Feasibilit 2 (August 1, 19	Systemic Production of Human y of Repeat Application to Obtai 997).			
		CHERINGTON, Van et al., "Retroviral Vector-Modified Bone Marrow Stromal Cells Secrete Biologically Act Factor IX <i>In Vitro</i> and Transiently Deliver Therapeutic Levels of Human Factor IX to the Plasma of Dogs Af Reinfusion", Human Gene Therapy, Vol. 9, pp. 1397-1407 (July 1, 1998).					
		<del>                                     </del>		of Biologically Active Human Fac ransduction", Human Gene The	tor IX in H	luman Hei 6, pp. 873	matopoietic Cells A 3-880 (July 1995).
Examiner				Date Considered			
*Examiner:	Initia	l if reference considere	d, whether or r	not citation is in conformance with next	h MPEP 6 t commun	09; draw l ication to	ine through citatior applicant.
	HULI	i comormance and not					

Form PTO 1449

## INFORMATION DISCLOSURE CITATION

				sheets if necessary)			34.	
	- 764	478.1442		Serial No.: Not Yet Assigned	1		559	
	Cla	aude NÉGRIER et al.					586	
	Со	ncurrently Herewith		Group	Not Yet	Assigned	jc =	
		·	U.S. PATE	NT DOCUMENTS		<sub>1</sub>		
_aminer Initial'	*	Document Number	Date	Name	Class	Sub Class	Filing Dat If Appropriate	
·								
			FOREIGN PA	TENT DOCUMENTS	<del>.  </del>	T. —	<u> </u>	
				Author, Title, Date, Pertinent				
		Globin Expression", Sc	ience, Vol. 216	ew Human Erythroleukemia C 5, pp. 1233-1235 (June 1982).				
	-	TABILIO, A. et al., "Exp Erythroleukemia Cell L	oression of Pla ine (HEL)". EM	telet Membrane Glycoproteins IBO J, Vol. 3, pp. 453-459 (198	and α-Gra 34). 	nule Protei	ns by a Human	
		LONG, Michael W. et al., "Regulation of Megakaryocyte Phenotype in Human Erythroleukemia Cells", Clinical Investigation, Vol. 85, pp. 1072-1084 (April 1990).						
		NISHIZUKA, Yasutomi, "The Role of Protein Kinase C in Cell Surface Signal Transduction and Tumour Promotion", Nature, Vol. 308, pp. 693-698 (April 19, 1984).						
		HONG, Ying et al., "Inhibition of Protein Kinase C Suppresses Megakaryocytic Differentiation and Stimulates Erythroid Differentiation in HEL Cells", Blood, Vol. 87, No. 1, pp. 123-131 (January 1, 1996).						
. •		HAAS, Thomas A. et al., "Integrin-Ligand Interactions: A Year in Review", Current Opinion in Cell Biology, Vol. 6, pp. 656-662 (1994).						
		UZAN, Georges et al., "cDNA Clones for Human Platelet GPIIb Corresponding to mRNA From Megakaryocytes and HEL Cells", Eur. J. Biochem., Vol. 171, pp. 87-93 (1988).						
		FRACHET, Philippe et al., "GPIIb and GPIIIa Amino Acid Sequences Deduced From Human Megakaryocyte cDNAs", Molecular Biology Reports, Vol. 14, pp. 27-33 (1990).						
		PRANDINI, M.H. et al. 5' Flanking Region", B (Oct. 14, 1988)	, "Isolation of t iochemical and	he Human Platelet Glycoprote I Biophysical Research Comm	in IIb Gene unications"	And Chara , Vol. 156,	No. 1, pp. 333-001	
	BRAY, Paul F. et al., "Platelet Glycoprotein Ilb", J. Clin. Invest., Vol. 80, pp. 1812-1817 (Dec. 1987).							
	۴۰	UZAN, Georges et al., "Tissue-Specific Expression of the Platelet GPIIb Gene", The Journal of Biological						
<del></del>					· · · · · ·	<del>-</del>		
,								
Examiner				Date Considered				
*Examiner:	Initial not in	if reference considered, conformance and not conformance.	whether or no onsidered. Inc	t citation is in conformance wit lude copy of this form with nex	h MPEP 60 t communic	9; draw line cation to ap	e through citation if oplicant.	
Form PTO 1449	9			Patent and Tradem	ark Office -	U.S. Depa	artment of Commerce	